Use of goserelin depot, a gonadotropin-releasing hormone agonist, for the treatment of menorrhagia and severe anemia in women with leiomyomata uteri

G. B. Candiani, P. Vercellini, L. Fedele, L. Arcaini, S. Bianchi, M. Candiani

Research output: Contribution to journalArticle

Abstract

Menorrhagia is the most frequent symptom in women with leiomyomata uteri. We induced transient hypoestrogenism with a gonadotropin-releasing hormone agonist, goserelin (Zoladex, I.C.I.), in a depot formulation, to resolve severe anemia in 16 women with uterine myomas. Subcutaneous administration of goserelin 3.6 mg was repeated every 28 days for 6 months. Thirteen patients became amenorrheic in 5 weeks and 3 reported scanty bleeding. Estradiol fell to postmenopausal levels after one month's treatment with hormonal surges on only three occasions. Uterine volume decreased by 49% after 3 months' treatment but subsequent reduction was not achieved. Mean hemoglobin rose from 7.4 g/dl pretreatment to 13.2 g/dl at 3 months (+78.3%) and mean hematocrit from 26.1% to 39.8% (+52.4%) without any further improvement. Serum ferritin increased constantly during the 6 months. Goserelin depot therapy in severely anemic patients with leiomyomas and menorrhagia is practical, safe and may avoid the need for preoperative transfusion.

Original languageEnglish
Pages (from-to)413-415
Number of pages3
JournalActa Obstetricia et Gynecologica Scandinavica
Volume69
Issue number5
Publication statusPublished - 1990

Fingerprint

Goserelin
Menorrhagia
Leiomyoma
Gonadotropin-Releasing Hormone
Uterus
Anemia
Myoma
Therapeutics
Ferritins
Hematocrit
Estradiol
Hemoglobins
Hemorrhage
Serum

Keywords

  • anemia
  • gonadotropin-releasing hormone agonists
  • leiomyomata uteri
  • menorrhagia

ASJC Scopus subject areas

  • Obstetrics and Gynaecology

Cite this

@article{09426306d51a4757a3fa75c9accb6369,
title = "Use of goserelin depot, a gonadotropin-releasing hormone agonist, for the treatment of menorrhagia and severe anemia in women with leiomyomata uteri",
abstract = "Menorrhagia is the most frequent symptom in women with leiomyomata uteri. We induced transient hypoestrogenism with a gonadotropin-releasing hormone agonist, goserelin (Zoladex, I.C.I.), in a depot formulation, to resolve severe anemia in 16 women with uterine myomas. Subcutaneous administration of goserelin 3.6 mg was repeated every 28 days for 6 months. Thirteen patients became amenorrheic in 5 weeks and 3 reported scanty bleeding. Estradiol fell to postmenopausal levels after one month's treatment with hormonal surges on only three occasions. Uterine volume decreased by 49{\%} after 3 months' treatment but subsequent reduction was not achieved. Mean hemoglobin rose from 7.4 g/dl pretreatment to 13.2 g/dl at 3 months (+78.3{\%}) and mean hematocrit from 26.1{\%} to 39.8{\%} (+52.4{\%}) without any further improvement. Serum ferritin increased constantly during the 6 months. Goserelin depot therapy in severely anemic patients with leiomyomas and menorrhagia is practical, safe and may avoid the need for preoperative transfusion.",
keywords = "anemia, gonadotropin-releasing hormone agonists, leiomyomata uteri, menorrhagia",
author = "Candiani, {G. B.} and P. Vercellini and L. Fedele and L. Arcaini and S. Bianchi and M. Candiani",
year = "1990",
language = "English",
volume = "69",
pages = "413--415",
journal = "Acta Obstetricia et Gynecologica Scandinavica",
issn = "0001-6349",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Use of goserelin depot, a gonadotropin-releasing hormone agonist, for the treatment of menorrhagia and severe anemia in women with leiomyomata uteri

AU - Candiani, G. B.

AU - Vercellini, P.

AU - Fedele, L.

AU - Arcaini, L.

AU - Bianchi, S.

AU - Candiani, M.

PY - 1990

Y1 - 1990

N2 - Menorrhagia is the most frequent symptom in women with leiomyomata uteri. We induced transient hypoestrogenism with a gonadotropin-releasing hormone agonist, goserelin (Zoladex, I.C.I.), in a depot formulation, to resolve severe anemia in 16 women with uterine myomas. Subcutaneous administration of goserelin 3.6 mg was repeated every 28 days for 6 months. Thirteen patients became amenorrheic in 5 weeks and 3 reported scanty bleeding. Estradiol fell to postmenopausal levels after one month's treatment with hormonal surges on only three occasions. Uterine volume decreased by 49% after 3 months' treatment but subsequent reduction was not achieved. Mean hemoglobin rose from 7.4 g/dl pretreatment to 13.2 g/dl at 3 months (+78.3%) and mean hematocrit from 26.1% to 39.8% (+52.4%) without any further improvement. Serum ferritin increased constantly during the 6 months. Goserelin depot therapy in severely anemic patients with leiomyomas and menorrhagia is practical, safe and may avoid the need for preoperative transfusion.

AB - Menorrhagia is the most frequent symptom in women with leiomyomata uteri. We induced transient hypoestrogenism with a gonadotropin-releasing hormone agonist, goserelin (Zoladex, I.C.I.), in a depot formulation, to resolve severe anemia in 16 women with uterine myomas. Subcutaneous administration of goserelin 3.6 mg was repeated every 28 days for 6 months. Thirteen patients became amenorrheic in 5 weeks and 3 reported scanty bleeding. Estradiol fell to postmenopausal levels after one month's treatment with hormonal surges on only three occasions. Uterine volume decreased by 49% after 3 months' treatment but subsequent reduction was not achieved. Mean hemoglobin rose from 7.4 g/dl pretreatment to 13.2 g/dl at 3 months (+78.3%) and mean hematocrit from 26.1% to 39.8% (+52.4%) without any further improvement. Serum ferritin increased constantly during the 6 months. Goserelin depot therapy in severely anemic patients with leiomyomas and menorrhagia is practical, safe and may avoid the need for preoperative transfusion.

KW - anemia

KW - gonadotropin-releasing hormone agonists

KW - leiomyomata uteri

KW - menorrhagia

UR - http://www.scopus.com/inward/record.url?scp=0025604947&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025604947&partnerID=8YFLogxK

M3 - Article

C2 - 2148663

AN - SCOPUS:0025604947

VL - 69

SP - 413

EP - 415

JO - Acta Obstetricia et Gynecologica Scandinavica

JF - Acta Obstetricia et Gynecologica Scandinavica

SN - 0001-6349

IS - 5

ER -